$CRVO
CervoMed Inc.

2020 Q4 Form 10-K Financial Statement

#000143774921006236 Filed on March 17, 2021

View on sec.gov

Income Statement

Concept 2020 Q4 2019 Q4 2019
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.480M $1.270M $4.830M
YoY Change 16.54% -10.56% -21.72%
% of Gross Profit
Research & Development $2.580M $1.660M $6.620M
YoY Change 55.42% 21.17% 15.08%
% of Gross Profit
Depreciation & Amortization $20.00K $30.00K $97.92K
YoY Change -33.33% 0.0% -11.29%
% of Gross Profit
Operating Expenses $4.090M $2.960M $6.620M
YoY Change 38.18% 4.96% 15.08%
Operating Profit -$11.55M
YoY Change -39.07%
Interest Expense $30.00K $30.00K $85.30K
YoY Change 0.0% 0.0% 2743.4%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$4.060M -$2.930M -$11.47M
YoY Change 38.57% -47.02% -39.03%
Income Tax $0.00 $820.0K $332.9K
% Of Pretax Income
Net Earnings -$4.060M -$3.750M -$11.80M
YoY Change 8.27% -32.68% -35.77%
Net Earnings / Revenue
Basic Earnings Per Share -$1.76
Diluted Earnings Per Share -$62.77K -$253.2K $6.707M
COMMON SHARES
Basic Shares Outstanding 64.02M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q4 2019 Q4 2019
SHORT-TERM ASSETS
Cash & Short-Term Investments $18.52M $14.18M $14.18M
YoY Change 30.61% 77.47% 77.47%
Cash & Equivalents $18.52M $14.18M $14.18M
Short-Term Investments
Other Short-Term Assets $260.0K $470.0K $470.0K
YoY Change -44.68% -48.91% -48.91%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $18.78M $14.65M $14.65M
YoY Change 28.17% 64.34% 64.42%
LONG-TERM ASSETS
Property, Plant & Equipment $149.2K $252.4K $500.0K
YoY Change -40.88% -27.95% 42.86%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $15.77K $322.3K $320.0K
YoY Change -95.11% 7.98% 6.67%
Total Long-Term Assets $8.953M $9.461M $9.460M
YoY Change -5.37% 1.86% 1.83%
TOTAL ASSETS
Total Short-Term Assets $18.78M $14.65M $14.65M
Total Long-Term Assets $8.953M $9.461M $9.460M
Total Assets $27.73M $24.11M $24.11M
YoY Change 15.01% 32.46% 32.47%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $545.8K $1.251M $1.250M
YoY Change -56.38% 529.43% 525.0%
Accrued Expenses $1.890M $470.0K $470.0K
YoY Change 302.13% -22.95% -22.95%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.436M $1.721M $1.720M
YoY Change 41.5% 114.1% 115.0%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $40.00K $140.0K $140.0K
YoY Change -71.43%
Total Long-Term Liabilities $40.00K $140.0K $140.0K
YoY Change -71.43%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.436M $1.721M $1.720M
Total Long-Term Liabilities $40.00K $140.0K $140.0K
Total Liabilities $2.915M $3.976M $3.980M
YoY Change -26.68% 53.5% 53.67%
SHAREHOLDERS EQUITY
Retained Earnings -$105.9M -$91.72M
YoY Change 15.47% 14.76%
Common Stock $130.7M $111.9M
YoY Change 16.87% 17.08%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $24.81M $20.13M $20.13M
YoY Change
Total Liabilities & Shareholders Equity $27.73M $24.11M $24.11M
YoY Change 15.01% 32.46% 32.47%

Cashflow Statement

Concept 2020 Q4 2019 Q4 2019
OPERATING ACTIVITIES
Net Income -$4.060M -$3.750M -$11.80M
YoY Change 8.27% -32.68% -35.77%
Depreciation, Depletion And Amortization $20.00K $30.00K $97.92K
YoY Change -33.33% 0.0% -11.29%
Cash From Operating Activities -$3.390M -$2.440M -$9.858M
YoY Change 38.93% -19.21% -8.49%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 10.47M 16.04M
YoY Change -100.0% 62.6%
NET CHANGE
Cash From Operating Activities -3.390M -2.440M -9.858M
Cash From Investing Activities
Cash From Financing Activities 0.000 10.47M 16.04M
Net Change In Cash -3.390M 8.030M 6.186M
YoY Change -142.22% -365.89% -783.33%
FREE CASH FLOW
Cash From Operating Activities -$3.390M -$2.440M -$9.858M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 dei Amendment Flag
AmendmentFlag
false
CY2020 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
33480365
CY2020 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020 dei Document Period End Date
DocumentPeriodEndDate
2020-12-31
CY2020 dei Document Type
DocumentType
10-K
CY2020 dei Entity Central Index Key
EntityCentralIndexKey
0001053691
CY2021Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
101903979
CY2020 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2020 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2020 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020Q2 dei Entity Public Float
EntityPublicFloat
62400000
CY2020 dei Entity Registrant Name
EntityRegistrantName
Diffusion Pharmaceuticals Inc.
CY2020 dei Entity Shell Company
EntityShellCompany
false
CY2020 dei Entity Small Business
EntitySmallBusiness
true
CY2020 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2020 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2020 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2020 dei Trading Symbol
TradingSymbol
dffn
CY2020Q4 dffn Accrued Clinical Studies Expenses Current
AccruedClinicalStudiesExpensesCurrent
1055398
CY2019Q4 dffn Accrued Clinical Studies Expenses Current
AccruedClinicalStudiesExpensesCurrent
57378
CY2020 dffn Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
19106504
CY2019 dffn Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
17415859
CY2020 dffn Class Of Warrant Or Rights Expired
ClassOfWarrantOrRightsExpired
0
CY2019 dffn Class Of Warrant Or Rights Expired
ClassOfWarrantOrRightsExpired
1767
CY2020Q2 dffn Deemed Dividend From Warrant Exchange
DeemedDividendFromWarrantExchange
2000000
CY2020 dffn Deemed Dividend From Warrant Exchange
DeemedDividendFromWarrantExchange
1950378
CY2019 dffn Deemed Dividend From Warrant Exchange
DeemedDividendFromWarrantExchange
CY2020Q4 dffn Deferred Tax Assets Capitalized Costs And Other
DeferredTaxAssetsCapitalizedCostsAndOther
10709631
CY2019Q4 dffn Deferred Tax Assets Capitalized Costs And Other
DeferredTaxAssetsCapitalizedCostsAndOther
9187898
CY2020Q4 dffn Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
38394
CY2019Q4 dffn Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
63589
CY2020Q4 dffn Deferred Tax Assets Orphan Drug Credits
DeferredTaxAssetsOrphanDrugCredits
541384
CY2019Q4 dffn Deferred Tax Assets Orphan Drug Credits
DeferredTaxAssetsOrphanDrugCredits
81700
CY2020Q4 dffn Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
38394
CY2019Q4 dffn Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
63589
CY2020 dffn Effective Income Tax Rate Reconciliation Orphan Drug Credits Percent
EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent
0.029
CY2019 dffn Effective Income Tax Rate Reconciliation Orphan Drug Credits Percent
EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent
-0.253
CY2020 dffn Offering Costs In Accounts Payable
OfferingCostsInAccountsPayable
CY2019 dffn Offering Costs In Accounts Payable
OfferingCostsInAccountsPayable
238232
CY2020Q4 dffn Prepaid Expenses Deposits And Other Assets
PrepaidExpensesDepositsAndOtherAssets
260825
CY2019Q4 dffn Prepaid Expenses Deposits And Other Assets
PrepaidExpensesDepositsAndOtherAssets
472464
CY2020 dffn Proceeds From Sale Of Common Stock Prefunded Warrants And Warrants
ProceedsFromSaleOfCommonStockPrefundedWarrantsAndWarrants
CY2019 dffn Proceeds From Sale Of Common Stock Prefunded Warrants And Warrants
ProceedsFromSaleOfCommonStockPrefundedWarrantsAndWarrants
12318956
CY2019 dffn Stock And Warrants Issued During Period Value Net Issuance Costs
StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts
11917895
CY2020 dffn Stock And Warrants Issued During Period Value Net Issuance Costs
StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts
10341631
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
545844
CY2020Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
653899
CY2019Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
182708
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
48338
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
614601
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
511433
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
130659550
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
111824859
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18515595
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14177349
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
515762
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
736119
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
736119
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
515762
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11340316
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
22694417
CY2020Q4 us-gaap Assets
Assets
27729551
CY2019Q4 us-gaap Assets
Assets
24110523
CY2020Q4 us-gaap Assets Current
AssetsCurrent
18776420
CY2019Q4 us-gaap Assets Current
AssetsCurrent
14649813
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14177349
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7991172
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18515595
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4338247
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
6186177
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
9100112
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
64015441
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1251412
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
31809
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
64015441
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
33480365
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
64016
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
33481
CY2020 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Concentration of Credit Risk</div></div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with multiple financial institutions, the balances of which frequently exceed federally insured limits.</div></div></div></div></div></div></div></div></div></div></div>
CY2020 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-1675381
CY2019 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
332885
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
2262072
CY2019Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
2287267
CY2020Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
443893
CY2019Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
2119274
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1818179
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
167993
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
3864189
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
1504496
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1571227
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1381750
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
14906646
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
12051440
CY2020Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
443893
CY2019Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
2119274
CY2020Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
2223678
CY2019Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
2223678
CY2020 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
56000
CY2019 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
68000
CY2020 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.04
CY2020 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.9
CY2020 us-gaap Depreciation
Depreciation
103168
CY2019 us-gaap Depreciation
Depreciation
97915
CY2020 us-gaap Depreciation Nonproduction
DepreciationNonproduction
103168
CY2019 us-gaap Depreciation Nonproduction
DepreciationNonproduction
97915
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.30
CY2019 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.76
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
53831973
CY2019 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
6706509
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.03
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.181
CY2020 us-gaap Nature Of Operations
NatureOfOperations
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">1.</div> Organization and Description of Business</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Diffusion Pharmaceuticals Inc., a Delaware corporation, an innovative biopharmaceutical company developing novel therapies that enhance the body's ability to deliver oxygen to the areas where it is needed most. The Company's lead product candidate, TSC, is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine's most intractable and difficult-to-treat conditions.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In addition to TSC, the Company's product candidate DFN-<div style="display: inline; font-style: italic; font: inherit;">529,</div> a novel, allosteric <div style="display: inline; font-style: italic; font: inherit;">PI3K/Akt/mTOR</div> pathway inhibitor, is in early-stage development. The Company previously completed <div style="display: inline; font-style: italic; font: inherit;">two</div> Phase <div style="display: inline; font-style: italic; font: inherit;">1</div> clinical trials evaluating DFN-<div style="display: inline; font-style: italic; font: inherit;">529</div> in age-related macular degeneration. DFN-<div style="display: inline; font-style: italic; font: inherit;">529</div> was also previously in preclinical development in oncology, specifically GBM.</div></div>
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
17890875
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
16044552
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.105
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.075
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.086
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.001
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.047
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.025
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6444109
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4834284
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-15860687
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11466494
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1675381
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
332885
CY2019 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
567668
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-518169
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-426774
CY2020Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
8639000
CY2019Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
8639000
CY2020 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
114257
CY2020 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
950602
CY2019 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
85302
CY2020Q4 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.1
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
158254
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
118519
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
39735
CY2020Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
9092
CY2020Q4 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P1Y109D
CY2020Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2020Q4 us-gaap Liabilities
Liabilities
2915369
CY2019Q4 us-gaap Liabilities
Liabilities
3976261
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
27729551
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
24110523
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2435783
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1721421
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13552629
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9858375
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-14185306
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-11799379
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-16135684
CY2019 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11799379
CY2020 us-gaap Open Tax Year
OpenTaxYear
2017 2018 2019
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-15974944
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-11551796
CY2020 us-gaap Operating Lease Expense
OperatingLeaseExpense
100000
CY2019 us-gaap Operating Lease Expense
OperatingLeaseExpense
100000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
149162
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
113469
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
111477
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
35693
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
135566
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
149162
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
247043
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1776470
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
358532
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
15771
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
322301
CY2020Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
35364
CY2019Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
70108
CY2020 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
982328
CY2019 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
162829
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
10827100
CY2019 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
CY2020 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
8046103
CY2019 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
3888425
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
763799
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
763799
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
149198
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
252366
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9427667
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6619597
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-105909384
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-91724078
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
CY2019 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
334205
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2240204
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
88.14
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
736119
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
515762
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1129733
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
15.64
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
147
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
172
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
11583
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
117270
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1931100
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.64
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.16
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
289067
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
203736
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
309276
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.28
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
55.78
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
289067
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2240204
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
8.28
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
276
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
142.50
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
83.81
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.62
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.68
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
219010
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y102D
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y357D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y328D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y328D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
700000
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
600000
CY2019 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2020 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2019 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
3888425
CY2020 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
7787476
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
24814182
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
20134262
CY2018Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
15611559
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
20134262
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
24814182
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Use of Estimates</div></div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The preparation of financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">On an ongoing basis, the Company evaluates its estimates using historical experience and other factors, including the current economic environment. Significant items subject to such estimates are assumptions used for purposes of determining stock-based compensation and accounting for research and development activities. Management believes its estimates to be reasonable under the circumstances. Actual results could differ significantly from those estimates.</div></div></div></div></div></div></div></div></div></div></div>

Files In Submission

Name View Source Status
0001437749-21-006236-index-headers.html Edgar Link pending
0001437749-21-006236-index.html Edgar Link pending
0001437749-21-006236.txt Edgar Link pending
0001437749-21-006236-xbrl.zip Edgar Link pending
dffn-20201231.xml Edgar Link completed
dffn-20201231.xsd Edgar Link pending
dffn-20201231_cal.xml Edgar Link unprocessable
dffn-20201231_def.xml Edgar Link unprocessable
dffn-20201231_lab.xml Edgar Link unprocessable
dffn-20201231_pre.xml Edgar Link unprocessable
dffn20201231_10k.htm Edgar Link pending
dffn20201231_10kimg001.gif Edgar Link pending
dffn20201231_10kimg003.gif Edgar Link pending
dffn20201231_10kimg004.gif Edgar Link pending
dffn20201231_10kimg005.gif Edgar Link pending
dffn20201231_10kimg006.gif Edgar Link pending
ex_234335.htm Edgar Link pending
ex_234411.htm Edgar Link pending
ex_234412.htm Edgar Link pending
ex_234413.htm Edgar Link pending
ex_234414.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rider.jpg Edgar Link pending
Show.js Edgar Link pending